Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?
Good
Peter
P
D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001321:Autistic Disorder / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008954:Models, Biological; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D009271:Naltrexone / Q000494:pharmacology* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D009292:Narcotic Antagonists; D009271:Naltrexone; D052247:Nitric Oxide Synthase Type II